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Abstract. Background: Histone deacetylase inhibitors
(HDACi) have been extensively studied as potential
candidates for treatment of various malignancies, including
leukemia, since they not only induce growth inhibition, cell
cycle arrest and apoptosis of cancer cells, but can also
increase the sensitivity of cancer cells to chemotherapeutic
drugs. The aim of this study was to investigate the effect of
two HDACi, trichostatin A (TSA) and valproic acid (VPA),
on etoposide-induced apoptosis in human leukemia cell
lines. Materials and Methods: Viability, apoptosis rate,
caspase activity, mitochondrial membrane potential and
expression of BCL2 mRNA were assessed in HL60 and U937
cell lines treated with 250 nM TSA or 1.25 mM VPA alone
or followed by 5 μM etoposide. Results: Preincubation of
HL60 cells with TSA or VPA significantly potentiated
etoposide-induced cytotoxicity and apoptosis, which was
associated with activation of caspases and loss of
mitochondrial membrane potential. Similar effects were not
observed in U937 cells. Expression of BCL2 mRNA was
strongly down-regulated after treatment of cells with HDACi
alone but did not show additive effect with etoposide.
Conclusion: Combination of HDACi with etoposide can
have a synergistic effect on increased apoptosis in leukemia
cells but this effect depends on the cancer cell type and
other factors such as the concentration of drugs and the
administration schedule.
Histone deacetylase inhibitors (HDACi) inhibit deacetylation
of both histones and nonhistone cellular proteins, inducing
histone acetylation and subsequent chromatin relaxation,
which facilitates transcription of target genes, especially
those involved in cell proliferation, differentiation and
apoptosis (1). Various HDACi have been described to cause
numerous effects in malignant cell lines including cell death,
induction of differentiation, cell-cycle arrest, enhanced
production of reactive oxygen species, altered cell migration,
and apoptosis (2-5). HDACi are therefore emerging as a
promising new class of anticancer agents with low toxicity
toward normal nonmalignant cells (6, 7).
Trichostatin A (TSA), the most common HDACi, is an
antifungal antibiotic derived from Streptomyces
hygroscopicus that inhibits mammalian histone deacetylase
classes I and II and effectively induces apoptosis in various
cancer cell types including leukemias (8-10). Valproic acid
(VPA), a class I selective HDACi already known for years as
an antiepileptic drug, has been also shown to exert
antileukemic activity (11-14).
HDACi are also being investigated in combination with
chemotherapeutic drugs in the treatment of malignant
diseases. Previous studies showed that TSA increased
sensitivity of gastric cancer cell lines to chemotherapeutic
drugs, including 5-fluorouracil, paclitaxel and irinotecan
(15). It was also reported that TSA potentiated the antitumor
effects of gemcitabine and cisplatin in human bladder cancer
cells (16, 17). Preclinical and clinical studies have shown
antileukemic effects when VPA was used in combination
with other chemotherapeutic agents including idarubicin
(18), 5-aza-2’-deoxycytidine (19), gemtuzumab ozogamicin
(20) and cytarabine (21). 
Etoposide is a widely used anticancer drug (22). It has
been shown that both etoposide and HDACi activities are
mediated by their interaction with topoisomerase II, which
leads to DNA strand breaks, inhibition of DNA replication,
and apoptotic cell death (23-26). Interestingly, in
combination treatment with HDACi and etoposide, both
agonist and antagonist effects on cytotoxicity have been
reported in different leukemia cell lines (26-30). 
In order to clarify this issue, we investigated the effect of
two HDACi, TSA and VPA, combined with etoposide, on
apoptosis in HL60 and U937 human leukemia cell lines.
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Materials and Methods
Drugs. TSA, VPA and etoposide were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). Stock solutions of drugs were
aliquoted and kept frozen at –20˚C. 
Cell culture. Cultures of HL60 (ATTC CCL 240) and U937 (ATCC
CRL 1593) cells (Manassas, VA, USA) were maintained in RPMI-
1640 medium supplemented with 10% fetal bovine serum, 2 mM L-
glutamine and 50 μg/ml gentamycine (all from Invitrogen, Grand
Island, NY, USA). Cells were cultured at 37˚C in a humidified (5%
CO2) atmosphere and were used for experiments in the phase of
exponential growth. They were seeded at 0.1×106/ml in 25 cm2
culture flasks (NUNC, Thermo Scientific, Roskilde, Denmark).
Cell proliferation assay. Cell growth was assessed by AlamarBlue
assay (Biosource, Camarillo, CA, USA), according to the
manufacturer’s instructions. Briefly, the cells were seeded into 96-well
plate at a density 2×104 cells per well (100 μl) in culture medium alone
or with drugs and incubated for a specified amount of time. After the
incubation period, AlamarBlue was added to the wells at a final
concentration of 10% and the plates were incubated for 4 hours at
37˚C in a humidified atmosphere containing 5% CO2. The intensity of
fluorescence emitted due to reduction of Alamar Blue was measured
with Microplate Fluorescence Reader FL600 (Bio-Tek Instruments,
Inc., VT, USA) (excitation: 530 nm, emission: 590 nm). Cell viability
was expressed as a percentage of the control viability (100%).
HDAC activity assay. HDAC activity was measured by using a
fluorescence HDAC Cell-Based Activity Assay Kit (Cayman
Chemical, Ann Arbor, MI, USA) according to the manufacturer’s
instructions. By using a cell-permeable HDAC substrate, the activity
of various protein lysine-specific deacetylases, including HDAC1-
containing complexes, can be measured in whole intact cells.
Briefly, cells were seeded in a 96-well clear-bottom black plate at a
density of 5×104 cells/well. The HDAC reaction was initiated by
adding 10 μl Boc-Lys(AC)-AMC substrate to each well, and the
incubation was carried out at 37˚C for 2 hours. The lysis/developer
solution was then added, and the mixture was incubated for 15
minutes at 37˚C. Fluorescence of samples was measured using
microplate fluorescence reader, with excitation at 360 nm and
emission at 460 nm. HDAC activity was expressed as a percentage
of that measured in control cells (100%).
Identification and quantification of apoptotic cells with Hoechst 33342.
Nuclear morphology of control and treated cells was studied by
fluorescence microscopy after staining cell nuclei with Hoechst 33342
(Sigma), as described previously (31), with some modifications. Briefly,
cytospin slides were washed in PBS (pH 7.4), fixed in formaldehyde
(4% solution in PBS) for 15 minutes at room temperature and then
incubated with Hoechst 33342 (5 μg/ml in distilled water) for 10
minutes at room temperature. They were then washed in PBS, mounted
in glycerin/PBS solution (1:2) and coverslipped. Cells (at least 200 per
slide) were examined under a fluorescence microscope (Olympus
BX50) equipped with MNU2 filter and the percentage of apoptotic cell
nuclei was calculated in each sample. 
Caspase activity assay. Caspase activity was measured using Apo-
ONE Homogeneous caspase-3/7 assay (Promega, Madison, WI,
USA) according to the manufacturer’s protocol. Cells were seeded
in a 384-well plate at 2×104 cells/20 μl per well in culture medium,
and 20 μl of caspase-3/7 reagent was added to each well. The
reaction was carried out for 2 hours at room temperature in the dark,
and the measurement of fluorescence was then performed in
microplate fluorescence reader with excitation wavelength of 485 nm
and emission wavelength 530 nm. Caspase activity was expressed as
relative fluorescence intensity (control cells: 100%).
Detection of changes in mitochondrial membrane potential Δψm.
The mitochondrial membrane potential was determined using a
fluorescence Mitochondrial Permeability Transition Detection kit
MitoPT™ JC-1 (AbD Serotec, Kidlington, Oxford, UK) according
to the manufacturer’s instructions. JC-1 dye exhibits potential-
dependent accumulation in the mitochondria indicated by a
fluorescence emission shift from green (~529 nm) to red (~590 nm).
Consequently, mitochondrial depolarization is indicated by a
decrease in the red/green fluorescence intensity ratio. Briefly, cells
were resuspended at a density of 1×106 cells in 1 ml of MitoPT™
JC-1 solution and were incubated for 15 minutes in the dark at 37˚C
in an atmosphere containing 5% CO2. After incubation, cells were
resuspended in the assay buffer and seeded in a 96-well clear
bottom black plate at a density of 1×105 cells/100 μl per well.
Fluorescence was monitored in a microplate fluorescence reader by
measuring both the monomer (527 nm emission; green) and J-
aggregate (590 nm emission; red) forms of JC-1 following 488 nm
excitation. Δψm was calculated as J-aggregate to monomer
fluorescence intensity ratio and in treated cells was expressed as a
percentage of the one in control cells (100%).
RNA isolation. In order to assess the expression of BCL2 mRNA,
total RNA was extracted from cultured cells using TRIzol reagent,
according to the protocol provided by the manufacturer (Invitrogen).
The concentration of total RNA was assessed by measuring the
absorbance at 260 nm, and RNA integrity was determined by 1.5%
agarose gel electrophoresis. The isolated RNA samples were stored
at –80˚C until RT-PCR analysis.
Reverse transcription of RNA. Total RNA from the cell samples was
reverse-transcribed using the Revert Aid™ H Minus First Strand
cDNA Synthesis Kit (Fermentas Life Science Europe, Bremen,
Germany) according to the manufacturer’s instructions. For reverse
transcription (RT), 3 μg of total RNA were mixed with 1 μl Oligo
d(T) primer (0.5 μg/μl) and water pretreated with
diethylpyrocarbonate (H2O-DEPC), and preincubated for 5 min at
70˚C. After preincubation, other components were added to the
mixture: 4 μl of 5× concentrated RT buffer (250 mM Tris–HCl, 250
mM KCl, 20 mM MgCl2, 50 mM DTT, pH 8.3 at 25˚C), 1 μl RNase
inhibitor (20 U/μl), and 2 μl deoxyribonucleotide triphosphates
(dNTPs, 10 mM). Following incubation at 37˚C for 5 min, 1 μl
RevertAid M-MuLV Reverse Transcriptase (200 U/μl) in a total
volume of 20 μl was added. The mixture was first incubated for 60
minutes at 42˚C, then for the final 10 minutes at 70˚C, and
subsequently stored at 20˚C.
Polymerase chain reaction (PCR). The PCR reactions were run in
total volumes of 25 μl containing: 2 μl of synthesized cDNA, 0.2
μM of each primer, 0.04 U/μl DNA polymerase in 10 mM buffer
Tris–HCl pH 8.8 (supplemented with 1.5 mM MgCl2, 50 mM KCl,
0.1% Triton X-100) (Finnzymes, Espoo, Finland), 0.2 mM dNTPs
(Roche, Mannheim, Germany) and H2O-DEPC. For the BCL2






































































































































gene, after an initial 5 minute denaturation at 94˚C, amplification
was performed under the following conditions: 94˚C for 30 s, 54˚C
for 30 s, and 72˚C for 90 s for 28 cycles, with the final incubation
at 72˚C for 8 minutes (32). For the β-actin gene, after an initial 5
minute denaturation at 94˚C, amplification was performed under
the following conditions: 94˚C for 30s, 54˚C for 30 s, and 72˚C
for 2 minutes for 28 cycles, with the final incubation at 72˚C for
8 minutes (33). β-Actin was used as an internal standard to
normalize all samples for potential variations in mRNA content.
The reaction products were analyzed by electrophoresis on 2.5%
agarose gel (Sigma Chemical Co.), stained with ethidium bromide,
directly visualized under UV light and photographed. The PCR
primer sets were as follows: 5’-GAC TTC GCC GAG ATG TCC
AG-3’ and 5’- TCA CTT GTG GCT CAG ATA GG-3’ for BCL2
(product size: 390 bp); 5’-CTG TCT GGC GGC ACC ACC AT -3’
and 5’-GCA ACT AAG TCA TAG TCC GC -3’ for β-actin
(product size: ~300 bp).
Statistical analysis. The results were expressed as means±SD of five
independent experiments. Statistical analysis was performed by use
of two-tailed Student’s t-test for unpaired data. p-values <0.05 were
considered statistically significant.
Results
Effects of TSA and VPA on cell viability, apoptosis and
HDAC activity. HL60 and U937 cells were exposed to
increasing concentrations of HDAC inhibitors: TSA (150 to
350 nM) or VPA (0.75 to 1.75 mM) for 24 hours. The cell
viability was inhibited by TSA and VPA in a dose-dependent
manner (Figure 1 A and B). No significant apoptosis
(increase up to ~5%) was induced by lower concentrations
of either HDACi. Concentrations higher than 250 nM of TSA
and 1.25 mM of VPA caused >10% increase in apoptosis in
both cell lines (Figure 1 C and D).
After TSA or VPA treatment the HDAC activity was
significantly reduced in both HL60 and U937 cells in a dose-
dependent manner (Figure 1 E and F).
Concentrations of 250 nM TSA and 1.25 mM VPA were
chosen for further studies, being the highest concentrations
having a relatively low toxic effect on the cells (~80%
viability and 5% increase in apoptosis). At these
concentrations of the drugs, HDAC activity was reduced to
approximately 30% in both cell lines (Figure 1 E and F).
Effect of etoposide after pretreatment with TSA or VPA. Cell
viability: HL60 and U937 cells were treated with 250 nM
TSA or 1.25 mM VPA for 24 hours before subsequent
treatment with 5 μM etoposide for 24 hours. The dose of
etoposide was selected to cause approximately 20% reduction
in cell viability. TSA and VPA alone had no significant effect
on cell viability in either cell line. Preincubation with TSA and
with VPA increased the sensitivity of HL60 cells to etoposide,
whereas in U937 cells, this effect was not observed (Figure 2).
Apoptosis: Apoptosis was assessed using Hoechst 33342-
stained cytospin preparations observed under fluorescence
microscopy (Figure 3 A-D).
Treatment with TSA or VPA alone did not induce a
significant increase in apoptosis of HL60 and U937 cells.
Etoposide-induced apoptosis was significantly potentiated
after pretreatment with TSA and VPA in HL60 cells but not
in U937 cells (Figure 3 E and F).
Caspase activity: TSA and VPA did not significantly alter
caspase-3/7 activity in HL60 and U937 cells. Treatment
with 5 μM etoposide induced a significant increase in
caspase activity in both cell lines compared to untreated
cells. The combination of TSA or VPA and etoposide
significantly increased the caspase activity compared to the
treatment with etoposide alone in HL60 cells, but not in
U937 cells (Figure 4).
Mitochondrial membrane potential (Δψm): Treatment with
TSA or VPA alone caused a slight decrease in Δψm, while
etoposide alone more strongly reduced Δψm in HL60 and
ANTICANCER RESEARCH 32: 2791-2800 (2012)
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Figure 2. Effect of etoposide on the viability of HL60 and U937 cells
pretreated with TSA (A) or VPA (B). Each value is the mean±SD of 5
measurements. Significant difference of cell viability from the corresponding
group of *untreated (control) cells (p<0.05) and from **etoposide-treated
cells (p<0.03).


































































































































































































































































U937 cells compared to untreated cells. The combined
treatment of HL-60 cells with TSA or VPA and etoposide
resulted in a significant reduction of Δψm compared to the
treatment with etoposide alone, but such an effect was not
observed in U937 cells (Figure 5).
BCL2 mRNA expression: As compared with untreated
cells, TSA and VPA as single agents reduced BCL2 mRNA
level in both cell lines. Expression of BCL2 mRNA also
decreased after treatment with TSA or VPA and etoposide
in HL60 cells. In U937 cells, inhibition of BCL2 mRNA
expression following treatment with TSA in combination
with etoposide was weaker as compared with that observed
after VPA and etoposide treatment. However, no significant
differences were observed in either cell line between BCL2
mRNA levels after treatment with a single HADCi and
after combined treatment with HADCi and etoposide
(Figure 6). 
Discussion
Apart from assessing the net apoptosis rate, we investigated
some apoptosis-related parameters: activity of caspases,
mitochondrial membrane potential and expression of BCL2
mRNA. Apoptosis is usually deregulated in cancer cells
because of increased expression of antiapoptotic proteins
and/or decreased expression of proapoptotic proteins (34).
Mitochondria are important regulators of extrinsic as well as
intrinsic apoptosis pathways, and loss of mitochondrial
membrane potential, accompanied by opening of
permeability transition pores, are early events in the
apoptotic cascade. Mitochondrial function is controlled by
several factors including pro- and antiapoptotic members of
the BCL2 family (35). 
In the present study, preincubation of HL60 promyelocytic
leukemia cells with 250 nM of TSA or 1.25 mM of VPA for
24 hours significantly potentiated etoposide-induced
ANTICANCER RESEARCH 32: 2791-2800 (2012)
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Figure 4. Effect of etoposide on caspase activity of HL60 and U937 cells
pretreated with TSA (A) and VPA (B). Each value is the mean±SD of 5
measurements. Significant difference of caspace activity from the
corresponding group of *untreated (control) cells (p<0.05) and from
**etoposide-treated cells (p<0.05).
Figure 5. Effect of etoposide on the change in mitochondrial membrane
potential (Δψm) of HL60 and U937 cells pretreated with TSA (A) and
VPA (B). Each value is the mean±SD of 5 measurements. Significant
difference of Δψm from the corresponding group of *untreated (control)
cells (p<0.05) and from **etoposide-treated cells (p<0.04).
apoptosis, which was associated with activation of caspases
and loss of mitochondrial membrane potential. Accordingly,
cell viability significantly decreased after combined
treatment with HDACi and etoposide.
Such an effect was not observed in U937 monocytic
leukemia cells after pretreatment with HDACi. As compared
to cells treated by etoposide alone, no significant changes in
apoptosis rate, caspase activity or mitochondrial membrane
potential were detected. This absence of a synergistic effect
of HDACi and etoposide could be at least partially related to
the weaker inhibition of BCL2 mRNA expression in U937
cells, observed especially after TSA and TSA with etoposide
treatments.
The enhanced caspase activity and decrease in
mitochondrial membrane potential mostly corresponded with
an increase in the net apoptosis rate after HDACi and
etoposide treatment. However, expression of BCL2 mRNA
was strongly down-regulated after treatment of cells with
HDACi alone and did not show any additive effect with
etoposide. It has been shown that antileukemia activities of
TSA and VPA can be explained by down-regulation of BCL2
(15). This suggests that other pro- or antiapoptotic factors are
also influenced by the combination treatment. As recently
demonstrated in lymphoma cells treated with HDACi and
etoposide or cisplatin, activation of caspases and up-
regulation of BES1-interacting Myc-like protein 3 (BIM3)
and BCL2-associated X protein (BAX) are not correlated
with BCL2 inhibition (36).
Our findings showing different response to HDACi
combined with etoposide in two different leukemia cell
lines correspond with results reported by other authors. On
one hand, HDACi were found to enhance etoposide-
triggered apoptosis in tumor cells (26, 36-41). On the other
hand, inhibition of apoptosis was also observed after such
treatment (27, 28, 42). Hauswald et al. (28) demonstrated
that HDACi, including TSA, may induce expression of
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Figure 6. Effect of etoposide (Eto) on BCL2 mRNA expression in HL60 and U937 cells pretreated with TSA and VPA in reverse transcription-PCR
analysis. β-Actin expression levels were used as controls for RNA.
multidrug resistance-associated genes in leukemia cells and
that combinations of HDACi and anticancer drugs can lead
to reduced cytotoxic effects by influencing multidrug
resistance-associated transport of drugs across the cell
membrane.
It should be noted that cell response to HDACi combined
with anticancer drugs can depend upon a variety of factors.
Leukemia cell lines display different phenotypes and bear
diverse chromosomal abnormalities (43). This variability can
in part explain some of the apparently conflicting results.
Another reason may relate to the differences in drug
concentrations and the exposure conditions used. Cytotoxicity
in combined treatment can be schedule-specific: synergistic
effect on lung tumor cells was observed when HDACi and a
DNA-damaging drug were applied simultaneously, while
sequential treatment (HDACi followed by etoposide or
cisplatin) caused an antagonistic effect (42).
In summary, combination of HDACi with anticancer
agents may induce increased apoptosis in cancer cells but
this effect depends on multiple factors, such as cancer cell
type, concentration of drugs within the range showing less
additive toxicity for normal cells, and administration
schedule. The influence of all these factors should be taken
into consideration in preclinical trials assessing the
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